{"doi":"10.1002/pbc.27704","title":"Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center","abstract":"<jats:title>Abstract</jats:title><jats:p>We retrospectively analyzed sequential therapy with romiplostim and eltrombopag in 23 children with immune thrombocytopenia: switching from romiplostim to eltrombopag (10 patients) or vice versa (13 patients). The median age of patients at enrollment in the study was 5.6 years (2‐15 years). Switching from romiplostim to eltrombopag was effective in eight (80%) patients, whereas switching from eltrombopag to romiplostim was effective in eight (62%) patients. The response rate was similar in patients failing the first thrombopoietin receptor agonist and those who had previous response. To date, all responders continue to maintain platelets over 50 × 10<jats:sup>9</jats:sup>/L at 13‐39 months after switching.</jats:p>","journal":"Pediatric Blood &amp; Cancer","year":2019,"id":680481,"datarank":0.32958368660043297,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.0,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1777928,"name":"Alexey A. Maschan","orcid":"0000-0002-0016-6698","position":1,"is_corresponding":false},{"id":1777929,"name":"Dina D. Baydildina","orcid":null,"position":2,"is_corresponding":false},{"id":1777930,"name":"Irina I. Kalinina","orcid":null,"position":3,"is_corresponding":false},{"id":1777931,"name":"Uliana N. Petrova","orcid":null,"position":4,"is_corresponding":false},{"id":1777932,"name":"Alexey V. Pshonkin","orcid":null,"position":5,"is_corresponding":false},{"id":1777933,"name":"Galina A. Novichkova","orcid":null,"position":6,"is_corresponding":false},{"id":1777927,"name":"Elena V. Suntsova","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center","abstract":"<jats:title>Abstract</jats:title><jats:p>We retrospectively analyzed sequential therapy with romiplostim and eltrombopag in 23 children with immune thrombocytopenia: switching from romiplostim to eltrombopag (10 patients) or vice versa (13 patients). The median age of patients at enrollment in the study was 5.6 years (2‐15 years). Switching from romiplostim to eltrombopag was effective in eight (80%) patients, whereas switching from eltrombopag to romiplostim was effective in eight (62%) patients. The response rate was similar in patients failing the first thrombopoietin receptor agonist and those who had previous response. To date, all responders continue to maintain platelets over 50 × 10<jats:sup>9</jats:sup>/L at 13‐39 months after switching.</jats:p>","is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30854783","pmcid":null,"openalex_id":"https://openalex.org/W2922116545","authors":[],"funders":[],"total_grants":0,"fwci":0.3223,"citation_percentile":0.59752066,"influential_citations":0,"citation_trend":[{"year":2021,"count":1},{"year":2022,"count":1},{"year":2023,"count":1},{"year":2025,"count":3},{"year":2026,"count":2}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpbc.27704","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27704","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/pbc.27704","host_type":"publisher"},{"url":"https://doi.org/10.1002/pbc.27704","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30854783","host_type":"repository"}],"fields_of_study":["Platelet Disorders and Treatments","Blood groups and transfusion","Chronic Lymphocytic Leukemia Research","Adolescent","Benzoates","Child","Child, Preschool","Chronic Disease","Female","Follow-Up Studies","Humans","Hydrazines","Male","Platelet Count","Prognosis","Purpura, Thrombocytopenic, Idiopathic","Pyrazoles","Receptors, Fc","Receptors, Thrombopoietin","Recombinant Fusion Proteins","Retrospective Studies","Severity of Illness Index","Tertiary Care Centers","Thrombopoietin"],"mesh_terms":["Adolescent","Benzoates","Child","Child, Preschool","Chronic Disease","Female","Follow-Up Studies","Humans","Hydrazines","Male","Platelet Count","Prognosis","Pyrazoles","Receptors, Fc","Recombinant Fusion Proteins","Retrospective Studies","Severity of Illness Index","Thrombopoietin","Purpura, Thrombocytopenic, Idiopathic","Receptors, Thrombopoietin","Tertiary Care Centers"],"keywords":["Eltrombopag","Romiplostim","Medicine","Thrombopoietin receptor","Thrombopoietin","Immune thrombocytopenia","Agonist","Internal medicine","Platelet","Pediatrics","Receptor","children","thrombopoietin receptor agonists"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T15:16:33.828004Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}